| 摘要 |
<p>Compositions, kits and methods for treating cancer in a subject involving one or more upstream activators and/or downstream effectors of the ten-eleven translocation (TET) methylcytosine dioxygenase 1 (TET1) are disclosed. Specifically, the disclosure provides methods for diagnosing a subject with at least one of a decreased survival rate, a poor prognosis, a faster progression of the cancer by analyzing a biological sample from the subject for the expression of high mobility group AT-hook 2 (HMGA2), TET1, and homeobox A (HOXA) genes including HOXA7 and HOXA9; and methods for treating cancer comprising administering a DNA demethylation agent.</p> |
